for people ages up to 90 years (full criteria)
at Oakland, California and other locations
study started
estimated completion



A global, multi-center, non-interventional Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

Official Title

CLARIFY: Autosomal Dominant Hypocalcemia Types 1 And 2 (ADH1/2) Disease Monitoring Study (DMS)


The ADH1 and ADH2 DMS is designed to better understand the disease burden of ADH1 and ADH2, how participants with ADH1 or ADH2 are managed with standard of care practices in a real-world setting, and how standard of care treatment impacts ADH1 and ADH2 symptoms.

The study will include adult and pediatric participants with a confirmed clinical diagnosis of ADH1 or ADH2. Each participant's data will be collected over a period of up to 5 years. In addition, retrospective (or past) data will be collected.


Autosomal Dominant Hypocalcemia, Autosomal Dominant Hypocalcemia Type 1 (ADH1), Autosomal Dominant Hypocalcemia Type 2 (ADH2), Hypocalcemia, Musculoskeletal Diseases, Muscular Diseases, Musculoskeletal Abnormalities, Calcium Metabolism Disorders, Metabolic Diseases, Hypoparathyroidism, Hypocalcemic Seizures, Hypercalciuria, Nephrocalcinosis, Nephrolithiasis, Calcium Sensing Receptor, Arthrogryposis


You can join if…

Open to people ages up to 90 years

  1. Have a documented activating variant of the CASR gene for ADH1 or documented activating variant of the GNA11 gene for ADH2 associated with a clinical syndrome of hypoparathyroidism prior to enrollment
  2. Be willing and able to provide informed consent or assent after the nature of the study and its details have been explained, and prior to any research-related procedures
  3. Be willing to provide access to prior medical records including imaging, biochemical, and diagnostic and medical history data, if available
  4. Be willing and able to comply with the study visit schedule and study procedures

You CAN'T join if...

  1. Have serious medical or psychiatric comorbidity that, in the opinion of the Investigator, would present a concern for participant safety or compromise the ability to provide consent or assent, or comply with the study visit schedule and study procedures
  2. Enrollment in an ADH1 or ADH2 interventional clinical study at the time of DMS Screening visit or at any point during the DMS


  • University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland accepting new patients
    Oakland California 94609 United States
  • Children's Hospital Colorado accepting new patients
    Aurora Colorado 80045 United States


accepting new patients
Start Date
Completion Date
Calcilytix Therapeutics, Inc., a BridgeBio company
Study Type
Expecting 60 study participants
Last Updated